More than 15 years have passed since the initial recognition of ampicillin resistance in clinical isolates of Haemophilus influenzae type b (9, 20) . Currently, between 10 and 30% of type b strains and between 3 and 30% of non-type b strains of H. influenzae are resistant to ampicillin (1, 4, 18) . The major mechanism of resistance is TEM-1 ,-lactamase activity. The other significant mechanism of resistance is the reduced affinity of certain penicillin-binding proteins for ampicillin (14, 20) .
An effective alternate therapeutic agent for the treatment of serious ampicillin-resistant H. influenzae infections is chloramphenicol. However, the potential hematologic toxicities of chloramphenicol therapy have resulted in the proliferation of newer antimicrobial agents with low toxicities. One orally administered agent, cefixime, has demonstrated broad-spectrum activity and may be useful in the treatment of respiratory tract infections (otitis media and sinusitis), including infections due to ampicillin-resistant H.
influenzae. It has demonstrated activity against H. influenzae in vitro, and its activity in the presence of a wide range of P-lactamases, including TEM-1, is unimpaired (3, 13, 17, 19 were .4 ,g/ml when tested at a concentration of 10' CFU/ml with supplemented brain heart infusion broth (Difco) in tube broth macrodilution (14-16). These 10 isolates were defined as ampicillin resistant, non-p-lactamase producing (Ampr NBLP). The ability of the isolates to produce ,B-lactamase was determined by using a nitrocefin-impregnated disk (BBL Microbiological Systems, Cockeysville, Md.). MICs were determined by using broth microdilution panels (PML Microbiologicals, Tualatin, Oreg.) containing Haemophilus test medium (8 Tables 1 and 2 , respectively. Tables 1 and 2 do not include data from tests of the 10 Ampr NBLP isolates. The serotype b isolates, as a group, were more susceptible to ampicillin, amoxicillin-clavulanic acid, cephalexin, cefaclor, cefuroxime, and cefixime (P < 0.05) than were the non-type b isolates. There was no statistical difference between serotype b and nontypeable isolates for susceptibility to amoxicillin or ceftriaxone. Ceftriaxone was the most active agent tested; MICs for 90% of (11-13, 17, 19) but three-to sixfold lower than those observed in some other studies (2, 10) .
The results of susceptibility testing of Ampr NBLP isolates are given in Table 3 . As a group, the Amp' NBLP isolates were significantly more resistant to amoxicillinclavulanic acid, cefixime, cefuroxime (P < 0.001), and cephalexin (P < 0.05) than were the other four phenotype groups tested. They were also more resistant to ampicillin and amoxicillin than were the two ampicillin-susceptible phenotype groups (P < 0.001) but more susceptible to ampicillin and amoxicillin than were the P-lactamase-producing phenotype groups (P < 0.001) (16) . There was no difference in the activity of ceftriaxone when any of the phenotypic groups were compared. Previous reports have (2, 19) higher than those in other reports for Ampr NBLP H. influenzae. Fuchs and associates (5, 6) have defined organisms whose MICs of cefixime were <1 ,i.g/ml as "susceptible" and those whose MICs were >1 but <4 ,ug/ml as "intermediate." Since the achievable concentration of cefixime in serum approaches only 4 jig/ml (5, 6) , the therapeutic efficacy of cefixime for these strains may be limited.
In conclusion, cefixime demonstrated activity comparable to that of other oral cephalosporins and penicillins in vitro against all of the phenotypic groups tested. However, its activity against some Amp' NBLP strains is significantly less than that of ceftriaxone, a comparative broad-spectrum cephalosporin included in this study.
